Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From breakthrough shingles vaccines to ViiV Healthcare’s HIV therapies, GSK’s science generates disclosures as complex as its pipeline. If you have ever wondered where the RSV launch costs are buried or how respiratory revenues move the needle, this page brings every document together and answers the questions people actually ask, like “GSK SEC filings explained simply� and “GSK insider trading Form 4 transactions.�
Stock Titan applies AI reading models to each new 20-F, 6-K, or proxy so you can skim instead of sift. Need the GSK quarterly earnings report 10-Q filing or an 8-K material events explained summary? You’ll see real-time alerts, plain-English highlights of vaccine safety data, and side-by-side comparisons of R&D spending. Our platform flags GSK Form 4 insider transactions real-time, traces option grants in the GSK proxy statement executive compensation section, and links each note to the relevant page in the PDF.
Whether you’re tracking patent-cliff timing, modelling Shingrix margins, or verifying GSK executive stock transactions Form 4, you’ll find everything here:
- Annual report 10-K simplified views (alongside the official 20-F)
- AI context for 6-K interim results and GSK earnings report filing analysis
- Instant download of exhibits that disclose trial halts, divestitures, or supply agreements
GSK has filed a Form 6-K announcing wide-ranging R&D agreements with China-based Hengrui Pharma.
Key terms:
- Exclusive ex-China licence for inhaled PDE3/4 inhibitor HRS-9821, now in clinical development for COPD as an add-on maintenance therapy.
- Framework to option up to 11 additional Respiratory, Immunology & Inflammation and Oncology programmes after phase I completion.
- Up-front payment: $500 m; potential success-based milestones of ~$12 bn plus tiered global royalties (ex-China).
- Hengrui funds and runs discovery through phase I; GSK controls later-stage development and worldwide commercialisation outside mainland China, Hong Kong, Macau and Taiwan.
Strategic rationale: complements GSK’s inhaled portfolio, extends pipeline visibility beyond 2031, and limits near-term cash burn while preserving global scale-up rights. Licence for HRS-9821 requires customary HSR antitrust clearance.
Omeros (OMER) filed an 8-K announcing a $22 million registered direct equity offering. The company will issue 5,365,853 new shares at $4.10—about a 14 % premium to the July 24 close—to Polar Asset Management Partners. After a 6 % placement fee payable to D. Boral Capital and other costs, net proceeds should approximate $20.3 million, closing on 28 July 2025.
Use of funds: general corporate purposes, R&D, and working capital. Cash & equivalents stood at ~$26 million on 18 July 2025; share count was 61.8 million, so the new issuance adds ~8.7 % dilution.
Pipeline updates: FDA accepted the March 2025 class-2 BLA resubmission for narsoplimab (TA-TMA). The PDUFA action date slipped from 25 Sep 2025 to 26 Dec 2025 after an FDA information request, although the company is negotiating to shorten the review. FDA analyses to date reportedly support efficacy; labeling talks are scheduled to begin no later than Oct 2025. The EMA validated the MAA, with an opinion expected mid-2026. In the PDE7 program, all NIDA-funded preclinical interaction studies are complete, but FDA asked for additional preclinical data before moving into a cocaine-use-disorder trial.
Strategic outlook: Omeros is negotiating an asset deal with potential multi-billion total value that could repay $84 million in debt and fund >12 months of operations; no assurance of completion.
GSK’s Form 6-K announces EU approval of Blenrep (belantamab mafodotin) combinations for adults with relapsed/refractory multiple myeloma. The anti-BCMA ADC may now be given with bortezomib + dexamethasone after �1 prior therapy or with pomalidomide + dexamethasone after prior lenalidomide exposure.
Authorisation is driven by Phase III data: DREAMM-7 nearly tripled median PFS to 36.6 m vs 13.4 m for a daratumumab triplet (HR 0.41, p<0.00001) and cut death risk 42 % (HR 0.58). DREAMM-8 showed PFS not yet reached vs 12.7 m for control at 21.8 m follow-up. Ocular adverse events were manageable, leading to �9 % discontinuations. This becomes the sixth global approval for Blenrep combos and the first EU label enabling use from first relapse, expanding addressable patients (~50 k new EU cases/yr) ahead of pending US and China reviews. No financial figures were disclosed.
GSK continued its 2025 share-buyback programme. On 23 July 2025 the company repurchased 491,680 ordinary shares (�0.012% of outstanding) at prices between 1,364.50 p and 1,374.50 p, yielding a volume-weighted average price of 1,369.42 p per share. All shares will be held in treasury.
Since the non-discretionary mandate with Merrill Lynch International commenced on 4 June 2025, 16,185,726 shares have been bought back. Treasury stock now totals 234,320,109 shares, representing 5.74 % of voting rights. The company’s share count (ex-treasury) stands at 4,081,064,171 shares, which is the new denominator for FCA transparency notifications.
The filing contains no earnings or strategic updates; it merely records routine execution of the authorised capital-return plan.
Key event: The FDA has extended the Biologics License Application review for GSK’s Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple myeloma, setting a new PDUFA action date of 23 October 2025—roughly three months later than previously expected.
Clinical support: The filing is underpinned by Phase III DREAMM-7 and DREAMM-8 data. DREAMM-7 nearly tripled median progression-free survival (36.6 m vs 13.4 m; HR 0.41, p<0.00001) and cut death risk by 42% (HR 0.58). DREAMM-8 showed a median PFS of 32.6 m vs 12.5 m (HR 0.49) with benefit across high-risk subgroups; overall-survival trend is positive but not yet significant.
Regulatory landscape: Blenrep combos are already approved in the UK, Japan, Canada, Switzerland and UAE, with ongoing reviews in the EU, China and other major markets.
Investor takeaway: While the three-month US delay defers potential revenue into late-2025, the robust efficacy profile remains intact, and GSK continues constructive FDA engagement.
GSK plc filed a Form 6-K detailing activity under its ongoing share buyback. On 22 Jul 2025 the company repurchased 506,734 ordinary shares (nominal value 31â…� p) via Merrill Lynch International at prices between 1,337.50 p and 1,359.00 p, generating a volume-weighted average price of 1,347.53 p. The stock will be held in treasury.
Since the non-discretionary agreement announced on 4 Jun 2025, GSK has bought back 15,694,046 shares. Post-transaction, treasury holdings rise to 233,828,429 shares (5.73 % of total voting rights), leaving 4,081,555,851 shares outstanding exclusive of treasury. The filing includes granular trade data for transparency and confirms the denominator for Disclosure Guidance & Transparency Rules reporting.
GSK plc disclosed that on 21 July 2025 it repurchased 504,228 ordinary shares (nominal 31¼ p) through Merrill Lynch International under its 4 June 2025 non-discretionary buy-back programme. Transaction prices ranged from 1,337p to 1,357p with a VWAP of 1,344.38p, representing a cash outlay of roughly £6.8 million. Since programme inception, 15,187,312 shares have been bought back.
All shares are held in treasury, increasing the treasury balance to 233,321,695 shares, now 5.72 % of total voting rights. Issued share capital (excluding treasury) stands at 4,082,062,585 shares, which becomes the denominator for FCA DTR calculations. No earnings, guidance or other financial data were included.
On 18 Jul 2025, GSK plc bought back 505,771 ordinary shares (nominal 31¼ p) through Merrill Lynch International as part of its previously announced non-discretionary buy-back programme.
The shares were purchased between 1,319.0 p and 1,360.5 p, with a volume-weighted average price of 1,344.42 p. Since the programme commenced on 4 Jun 2025, GSK has repurchased 14,683,084 shares.
Following this latest transaction, the company now holds 232,817,467 shares in treasury, representing 5.70 % of total voting rights. Shares outstanding (excluding treasury) stand at 4,082,566,813, which investors should use as the denominator when assessing disclosure thresholds under the FCA’s DTR rules.
The filing contains no new earnings or guidance; it solely updates the market on the progress of GSK’s authorised share-repurchase programme.
FAQ
What is the current stock price of GSK PLC (GSK)?
What is the market cap of GSK PLC (GSK)?
What is the core business of GSK PLC?
Which therapeutic areas does GSK specialize in?
How does GSK generate revenue?
What role do joint ventures play in GSK's business model?
How is GSK positioned within the competitive pharmaceutical landscape?
What distinguishes GSK's research and development efforts?
In which geographical markets does GSK operate?
What key strengths contribute to GSK's success?
